Response rate and early mortality for patients with MDS and AML
| Characteristics . | Cohort . | ||
|---|---|---|---|
| AML ITT (n = 21), n (%) . | AML ITT-PP (n = 19),∗ n (%) . | HR-MDS (n = 6), n (%) . | |
| Overall survival, mo | 16.1 | 9.6 | |
| ORR (CR + CRi + MLFS) ORR (CR + mCR) | 12 (57) | 12 (63) | 4 (67) |
| CR/CRi | 11 (52) | 11 (58) | |
| Best response | |||
| CR | 10 (48) | 10 (53) | 3 (50) |
| mCR | 1 (17) | ||
| CRi | 1 (5) | 1 (5) | 2 (33) |
| MLFS | 1 (5) | 1 (5) | |
| No response | 9 (43) | 7 (37) | |
| MRD− (hematologics flow) | 9 (43) | 9 (47) | 4 (67) |
| Median duration of response, mo (range)∗ | 5.5 (3.9 to NR) | 5.2 (4.8 to NR) | |
| Mortality rate at 8 wk | 0 | 0 | 0 |
| Characteristics . | Cohort . | ||
|---|---|---|---|
| AML ITT (n = 21), n (%) . | AML ITT-PP (n = 19),∗ n (%) . | HR-MDS (n = 6), n (%) . | |
| Overall survival, mo | 16.1 | 9.6 | |
| ORR (CR + CRi + MLFS) ORR (CR + mCR) | 12 (57) | 12 (63) | 4 (67) |
| CR/CRi | 11 (52) | 11 (58) | |
| Best response | |||
| CR | 10 (48) | 10 (53) | 3 (50) |
| mCR | 1 (17) | ||
| CRi | 1 (5) | 1 (5) | 2 (33) |
| MLFS | 1 (5) | 1 (5) | |
| No response | 9 (43) | 7 (37) | |
| MRD− (hematologics flow) | 9 (43) | 9 (47) | 4 (67) |
| Median duration of response, mo (range)∗ | 5.5 (3.9 to NR) | 5.2 (4.8 to NR) | |
| Mortality rate at 8 wk | 0 | 0 | 0 |
ITT-PP, ITT per protocol.
DOR was evaluated from the time of response after 12 weeks of induction until progression.